Adiso Therapeutics

At Adiso, we create medicines to treat inflammatory diseases, to improve the lives of patients and their families. We believe that current therapeutic approaches are often inadequate to halt disease progression or run the risk of burdening the patient with significant safety concerns.

To tackle these challenges, we are advancing an innovative pipeline of multi-modal agents all with novel mechanisms of action and a precision therapeutic approach.

• ADS051 is a first-in-class, oral, gut-restricted modulator of neutrophil trafficking and activation small molecule for the treatment of ulcerative colitis that has completed a Phase 1b MAD clinical trial and will be moving into Phase 2 development later this year.
• ADS032 is a first-in-class dual inflammasome inhibitor (NLRP1 & NLRP3) small molecule in advanced pre-clinical development for the treatment of respiratory and dermal inflammation.
• ADS024 is an orally dosed, naturally occurring single strain live biotherapeutic product (SS-LBP) with selective activation of the lysophosphatidic acid receptor 3 (LPAR3), a G-protein coupled receptor of the most druggable class. ADS024 has shown efficacy in an Alzheimer’s model and in 12 other animal models of 7 additional neurodegenerative/neuroinflammatory diseases.